Page 73 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Predictive value of interim PET in DLBCL Supplemental Table 3A Meta-regression analyses. Prognostic.
Subgroup
Study design % DLBCL Visual Criteria Scanner* Radiotherapy ASCT upfront
Blinded review
Outcome measure
Reference Control prospective retrospective 100% DLBCL 80-99% DLBCL Deauville
IHP
PET/CT
PET/CT + standalone yes
unknown/no
yes
no
unknown
yes
unknown/no
PFS
EFS
No of studies
6 12 15 3 11 3 12 5
9 8/1 2
5 11 9 8/1 14 4
HR of reference group
3·17 (95%CI 2·13-4·73)
2·84 (95% CI 2·29-3·52) 4·55 (95% CI 2·94-7·03) 3·21 (95% CI 1·51 -5·19)
2·85 (95%CI 2·28-3·56) 4·39 (95% CI 3·15-6·10) 2·88 (95%CI 2·13-3·89)
P value
0·9369 0·0577 0·6997 0·0332 0·4069
4·96 (95% CI 2·40-10·21)
0·2073
3·12 (95%CI 2·31-4·21) 2·87 (95% CI 2·28-3·62)
0·2126 0·9653
0·1495
P value
NS
0·0503 (accuracy)
NS NS
NS NS NS NS NS
Supplemental Table 3B Meta-regression analyses. Diagnostic.
Subgroup
Study design % DLBCL
Visual Criteria Scanner*
Radiotherapy ASCT upfront
Blinded review
Outcome measure
Reference
prospective 100% DLBCL
Deauville PET/CT
yes yes
yes PFS
No of studies
7 16
12 12
10 2
10 15
Moderator
retrospective 80-99% DLBCL
IHP
PET/CT + standalone
unknown/no no
unknown unknown/no EFS
No of studies
12 3
3 6
9 5 12 9 4
NS= not significant
*No information about type of PET system for one study
71
3